Genzyme Myozyme BLA For Pompe Disease Could Clear FDA By January
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme expects its BLA for Myozyme (alglucosidase alfa) will receive a priority review from FDA for treatment of Pompe disease, the firm said July 29
You may also be interested in...
Myozyme User Fee Goal Extended Until April
Genzyme says the extension for the Pompe disease treatment is intended to provide the FDA time to review clarifying information.
Myozyme User Fee Goal Extended Until April
Genzyme says the extension for the Pompe disease treatment is intended to provide the FDA time to review clarifying information.
Genzyme Predicts $5 Bil. In Annual Revenues By 2010 From Current Portfolio
The firm is anticipating its forthcoming Pompe disease therapy Myozyme to contribute to growth starting in 2006.